DUBLIN, Oct. 6, 2022
/PRNewswire/ -- Mallinckrodt plc
(OTCMKTS: MNKPF) ("Mallinckrodt" or the
"Company"), a global specialty pharmaceutical company, today
announced that it has appointed Susan
Silbermann to its Board of Directors, effective October 5, 2022. With the addition of Ms.
Silbermann, the Mallinckrodt Board will expand to nine directors,
eight of whom are independent.
"Susan is a highly respected and deeply experienced global
executive in the healthcare industry, and we are pleased to welcome
her to Mallinckrodt's Board," said
Paul Bisaro, Chairman of the
Mallinckrodt Board of Directors. "Susan brings an important
perspective, with decades of leadership experience across
established and unique healthcare brands. We look forward to
benefiting from her deep expertise and insights as we continue to
strengthen the organization, sharpen our execution and deliver
innovative therapies for patients."
"I am excited to join the Mallinckrodt Board at this
transformative moment for the Company," said Ms. Silbermann. "With
a strong platform in place, I see compelling opportunities ahead to
grow the business, develop the pipeline and, most importantly,
serve the many patients who can benefit from Mallinckrodt's products. I look forward to helping
the Company deliver on its patient-first business priorities as we
generate long-term value for Mallinckrodt shareholders."
During her 34-year career at Pfizer, Ms. Silbermann held
numerous positions of increasing responsibility spanning public
health, marketing, commercial development and general management in
U.S. and international markets. As Chair of the Pfizer Global
COVID-19 Task Force, she developed and led an organization-wide
task force overseeing the safety and well-being of 100,000
colleagues in more than 100 countries. Alongside this role, Ms.
Silbermann served as Global President, Emerging Markets from 2018
to 2020, with operational and managerial responsibility for the
entire Pfizer portfolio in China,
Asia, Latin America, Africa and the Middle East, including the initial supply of
COVID-19 vaccines in these regions. From 2012 to 2018, she served
as President and General Manager, Pfizer Vaccines, creating the
basis for much of Pfizer's current vaccine pipeline and portfolio
and establishing and leading one of three inaugural global business
units at Pfizer. Previously, Ms. Silbermann held the titles of
Regional President, Latin America
and Senior Vice President, Commercial Development at Pfizer.
Ms. Silbermann currently serves on the boards of LianBio and
HilleVax, Inc. She also serves on the board of IAVI, an NGO focused
on advancing vaccines and medicines for HIV-AIDS and other emerging
infectious diseases, and is a board member for Meet the Writers, an
education non-profit.
Ms. Silbermann holds a B.S. in Biology and French from
Tufts University, an M.B.A. in
Marketing and International Business from New
York University and a Master of Administration degree in
French Social and Political Sciences from New
York University.
About Mallinckrodt
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The Company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, hepatology,
nephrology, pulmonology, ophthalmology and oncology; immunotherapy
and neonatal respiratory critical care therapies; analgesics;
cultured skin substitutes and gastrointestinal products. Its
Specialty Generics reportable segment includes specialty generic
drugs and active pharmaceutical ingredients. To learn more about
Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including statements regarding Mallinckrodt's future financial condition and
operating results, legal, economic, business, competitive and/or
regulatory factors affecting Mallinckrodt's businesses, and any other statements
regarding events or developments Mallinckrodt believes or anticipates will or may
occur in the future, may be "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
and involve a number of risks and uncertainties. There are a number
of important factors that could cause actual events to differ
materially from those suggested or indicated by such
forward-looking statements and you should not place undue reliance
on any such forward-looking statements. The "Risk Factors" section
of Mallinckrodt's Annual Report on Form
10-K for the fiscal year ended December 31,
2021, as updated by Mallinckrodt's Quarterly Report on Form 10-Q for
the quarterly period ended July 1,
2022 and other filings with the SEC identify and describe in
more detail the risks and uncertainties to which Mallinckrodt's businesses are subject. The
forward-looking statements made herein speak only as of the date
hereof and Mallinckrodt does not assume
any obligation to update or revise any forward-looking statement,
whether as a result of new information, future events and
developments or otherwise, except as required by law.
CONTACTS
Investor Relations
Daniel J. Speciale
Global Corporate Controller and Chief Investor Relations
Officer
314-654-3638
daniel.speciale@mnk.com
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura
Reinhard
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of
a Mallinckrodt company. Other brands are trademarks of
a Mallinckrodt company or their respective
owners. ©2022 10/22.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-announces-appointment-of-susan-silbermann-to-its-board-of-directors-301642185.html
SOURCE Mallinckrodt plc